CTOs on the Move

Academy of Psychosematic Medicine

www.apm.org

 
Academy of Psychosematic Medicine is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.apm.org
  • 5272 River Rd Ste 630
    Bethesda, MD USA 20816
  • Phone: 301.718.6520

Executives

Name Title Contact Details

Similar Companies

SoftScript

SoftScript is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VillaSport Athletic Club and Spa

We would love to welcome you to VillaSport - the only place where fitness, family and community all come together.

Current Health

Current Health offers an enterprise care-at-home platform to enable healthcare organizations to deliver high-quality, patient-centric care at a lower cost. The company integrates patient-reported data with data from biosensors – including their own continuous monitoring wearable device – to provide healthcare organizations with actionable, real-time insights into the patient’s condition. Leveraging clinical algorithms that can be tailored to the individual patient, Current Health identifies when a patient needs clinical attention, allowing organizations to manage patient care remotely or coordinate in-home care via our integrated service partners. The Current Health platform brings together telehealth capabilities, patient engagement tools, and in-home connectivity to provide a single solution to manage all care in the home.

Designing Health

Designing Health Incorporated is a Valencia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China. Our mission is to become an integrated biopharmaceutical company with significant market share in China, while establishing partnerships for global development and commercialization. Part of our strategy is to leverage our expertise and resources in North America and China to bring safer, more effective, and/or easier-to-use drugs to patients and to develop them more cost-effectively and faster using our unique dual development approach.